Find Funding Opportunities

The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) hereby notify Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) holding specific types of NIH research grants, listed in the full Funding Opportunity Announcement (FOA) that funds are available for administrative supplements to improve the diversity of the research workforce by supporting and recruiting students, postdoctorates, and eligible investigators from groups that have been shown to be underrepresented in health-related research. This supplement opportunity is also available to PD(s)/PI(s) of research grants who become disabled and need additional support to accommodate their disability in order to continue to work on the research project. Administrative supplements must support work within the scope of the original project.

The Office of Research on Womens Health (ORWH), participating Institutes and Centers (ICs) of the National Institutes of Health (NIH), and the Office of Dietary Supplements (ODS) announce the continuation of the program for administrative supplements to research grants to support individuals with high potential to re-enter an active research career after an interruption for family responsibilities or other qualifying circumstances. The purpose of these supplements is to encourage such individuals to re-enter research careers within the missions of all the program areas of NIH. This program will provide administrative supplements to existing NIH research grants for the purpose of supporting full-time or part-time research by these individuals to update their existing research skills and knowledge.

The purpose of the U.S.-China Program for Biomedical Collaborative Research is to stimulate collaborative basic, translational, and applied research between United States (U.S.)-based researchers and Chinese researchers in the areas of allergy, immunology, and infectious diseases including HIV/AIDS and its co-morbidities and co-infections, cancer, mental health, Parkinsons disease (PD), and stroke.

The NINDS recognizes the unique and compelling need to promote diversity in participation in neuroscience research and expects these efforts to diversify the neuroscience research workforce to lead to the recruitment of the most talented researchers from all groups. The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research is to provide junior faculty support and protected time (up to three years) for an intensive, supervised career development experience in neuroscience research. The goal of the NINDS K01 is to diversify the pool of independent neuroscience research investigators and to enhance the probability of success in obtaining independent NIH or other independent research support. Individuals from backgrounds underrepresented in biomedical research are eligible for support under this award if they have doctoral research degrees (Ph.D. or equivalent) and are in the first 3 years of a faculty position at the time of award.

The purpose of this limited Funding Opportunity Announcement (FOA) is to invite applications to support the Data Coordinating Center (DCC) for the Cardiothoracic Surgical Trials Network (CTSN). A separate FOA (RFA-HL-13-017) seeks applications for Network Core Clinical Centers. The goal of the CTSN is to evaluate surgical interventions and related management approaches to improve the treatment of cardiovascular disease and conditions in adult patients. The DCC provides administrative and statistical support to maintain an infrastructure to develop, coordinate, and conduct multiple collaborative surgical trials designed to improve cardiovascular outcomes and optimize post-operative neurological function.

The purpose of this funding opportunity announcement (FOA) is to stimulate innovation and development of technologies and reagents that will accelerate the discovery of biological biomarkers for Parkinsons disease (PD). It is expected that the NINDS Parkinsons disease biomarkers program (PDBP) will consolidate, integrate and enhance NINDS-funded PD biomarkers research projects. This FOA will foster research into biospecimen preparation methodologies, quantitative analyte analysis, reagent and assay development, and data analysis methods needed for PD biomarkers progress to occur. Utilization of extant specimens and data for novel discovery projects is permitted under this FOA, as long as consent enables deposition of all data into the PDBP Data Management Resource (DMR).

The purpose of this funding opportunity announcement (FOA) is to 1) support hypothesis driven clinical research to discover biomarkers that will improve the efficiency and outcome of Phase II clinical trials for Parkinsons Disease (PD) and 2) support the collection of clinical data and new biological specimens that will be used for biomarker exploratory efforts under the NINDS Parkinsons Disease Biomarkers Program (PDBP). Applications may include both of these goals if justified. Studies using either existing or new cohorts may be appropriate. For all applications, applicants must describe statistical justification for the number of subjects/samples proposed and a clear scientific rationale for the range and types of subjects/samples to be collected. Broad sharing of data and biological specimens with academic, industry and government researchers is a critical feature of the PDBP generally and of this FOA specifically, in order to provide valuable research resources for the scientific community to advance Parkinsons Disease research in an efficient and effective manner (consistent with applicable laws, regulations, and policies); therefore, all subjects in any proposed study must be properly consented to allow appropriate sample and data distribution to researchers in academics and industry.

On February 7, 2012, Secretary of Health and Human Services Kathleen Sebelius announced that $50 million would be directed immediately to boost Alzheimers research in FY2012 in response to President Obama signing the National Alzheimer's Project Act. This increased funding will likely cover a range of projects, including basic science on the biology and genetics of Alzheimers disease as well as translational and clinical research in development and testing of therapies. The purpose of this funding opportunity announcement is to solicit Small Business Innovation Research (SBIR) applications from eligible small business concerns in the area of Alzheimer's disease.

On February 7, 2012, Secretary of Health and Human Services Kathleen Sebelius announced that $50 million would be directed immediately to boost Alzheimers research in FY2012 in response to President Obama signing the National Alzheimer's Project Act. This increased funding will likely cover a range of projects, including basic science on the biology and genetics of Alzheimers disease as well as translational and clinical research in development and testing of therapies. The purpose of this funding opportunity announcement is to solicit Small Business Technology Transfer Research (STTR) applications from eligible small business concerns in the area of Alzheimer's disease.

The National Institutes of Health (NIH) announces a unique opportunity for investigators working with small molecule compounds to gain access to a robust virtual pharma network to discover neurotherapeutic drugs. Successful applicants to this FOA will become collaborative participants in this network, receiving both funding and no-cost access to contracted drug discovery services that are not typically available to the academic research community. Funding will be provided through a U01 cooperative agreement mechanism to conduct biological testing of compound analogs in disease assays and models in the investigators laboratory. No-cost drug discovery services will also be provided, including medicinal chemistry optimization, IND-directed pharmacology and toxicology, and Phase I clinical testing. Researchers in possession of disease assays and small molecule compounds that show promise for treating nervous system and psychiatric disorders, but that are not yet suitable for clinical testing, are strongly encouraged to apply.